Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVER001 in Selected Proteinuric Glomerular Diseases
NCT07614477Phase 2Recruiting
- Sponsor
- Everest Medicines
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ever001 in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), IgA nephropathy (IgAN), sponsored by Everest Medicines. Started May 2026; status: recruiting.
02
Drugs
ever001
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07614477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614477.